Thiazolidinedione safety
- PMID: 22616948
- DOI: 10.1517/14740338.2012.691963
Thiazolidinedione safety
Abstract
Introduction: Thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk-benefit analysis to determine what role TZDs should play in our current treatment of type 2 diabetes and where the future of this class of drugs is headed.
Areas covered: This review provides a comprehensive overview of the literature from 2000 onward reporting the known side effects of rosiglitazone and pioglitazone, with commentary on the quality of the data available, putative mechanism of each side effect and clinical significance. Finally, a perspective on the future of the TZDs as a class is provided.
Expert opinion: The current TZDs are first-generation, non-specific activators of peroxisome proliferator-activated receptor (PPAR) gamma, resulting in a wide array of deleterious side effects that currently limit their use. However, the development of highly targeted selective PPAR gamma modulators (SPPARγMs) and dual PPAR gamma/alpha agonists is on the horizon.
Similar articles
-
Examining the safety of PPAR agonists - current trends and future prospects.Expert Opin Drug Saf. 2013 Jan;12(1):65-79. doi: 10.1517/14740338.2013.741585. Epub 2012 Nov 8. Expert Opin Drug Saf. 2013. PMID: 23134541 Review.
-
The safety of thiazolidinediones.Expert Opin Drug Saf. 2011 May;10(3):419-28. doi: 10.1517/14740338.2011.534982. Epub 2011 Mar 3. Expert Opin Drug Saf. 2011. PMID: 21366501 Review.
-
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?Diab Vasc Dis Res. 2005 May;2(2):61-6. doi: 10.3132/dvdr.2005.010. Diab Vasc Dis Res. 2005. PMID: 16305060 Review.
-
Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.Hosp Pract (1995). 2013 Apr;41(2):132-47. doi: 10.3810/hp.2013.04.1062. Hosp Pract (1995). 2013. PMID: 23680744
-
The current role of thiazolidinediones in diabetes management.Arch Toxicol. 2016 Aug;90(8):1861-81. doi: 10.1007/s00204-016-1737-4. Epub 2016 May 10. Arch Toxicol. 2016. PMID: 27165418 Review.
Cited by
-
Cladosporols and PPARγ: Same Gun, Same Bullet, More Targets.Biomolecules. 2024 Aug 13;14(8):998. doi: 10.3390/biom14080998. Biomolecules. 2024. PMID: 39199386 Free PMC article. Review.
-
Thermogenic Fat as a New Obesity Management Tool: From Pharmaceutical Reagents to Cell Therapies.Biomedicines. 2024 Jul 4;12(7):1474. doi: 10.3390/biomedicines12071474. Biomedicines. 2024. PMID: 39062047 Free PMC article. Review.
-
A Combined Molecular Dynamics and Hydropathic INTeraction (HINT) Approach to Investigate Protein Flexibility: The PPARγ Case Study.Molecules. 2024 May 10;29(10):2234. doi: 10.3390/molecules29102234. Molecules. 2024. PMID: 38792097 Free PMC article.
-
Effects of Pharmaceutical Substances with Obesogenic Activity on Male Reproductive Health.Int J Mol Sci. 2024 Feb 15;25(4):2324. doi: 10.3390/ijms25042324. Int J Mol Sci. 2024. PMID: 38397000 Free PMC article. Review.
-
A glimpse of the connection between PPARγ and macrophage.Front Pharmacol. 2023 Aug 28;14:1254317. doi: 10.3389/fphar.2023.1254317. eCollection 2023. Front Pharmacol. 2023. PMID: 37701041 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
